US Supreme Court Temporarily Extends Mail-Order Access to Abortion Pill
The United States Supreme Court has temporarily maintained mail-order access to mifepristone, a widely used abortion medication, pending a final decision on the merits of the case. This ruling extends a suspension of a May 1 decision by a conservative appeals court that had sought to block postal distribution of the drug. The emergency appeal was filed by manufacturers Danco Laboratories and GenBioPro, who warned that restricting teleprescribing and mailing would cause immediate confusion and disrupt sensitive medical timelines for patients nationwide. While the decision provides temporary relief, reproductive rights advocates express concern that access remains threatened by ongoing legal challenges and a politically motivated safety review initiated by the Trump administration and the FDA. Conservative justices Samuel Alito and Clarence Thomas dissented from the order. Anti-abortion groups, including Pro-Life America, voiced deep disappointment with the outcome. Mifepristone is involved in nearly two-thirds of abortions in the US, where federal protections were removed in 2022, leaving regulation to individual states, many of which have enacted strict bans or limitations.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection